For example, selpercatinib and pralsetinib inhibit mutant RET in MTC but they can also block the RET fusion proteins-mediated signaling found in PTC and other types of tumor (such as lung cancer) as documented by enduring high partial response and several complete responses rates in Phase III trials (83, 84). The gene discussed is RET; the disease is lung carcinoma.